SOMERSET, N.J., May 3, 2010 (GLOBE NEWSWIRE) -- Tamir Biotechnology, Inc. (formerly known as Alfacell Corporation) (OTCQB:ACEL) filed a resale registration statement on Form S-1 on April 30, 2010 with the Securities and Exchange Commission to register all the shares of common stock issuable upon conversion of the notes and exercise of the warrants that were previously sold by the company in a $3.25 million private placement closed in October 2009. As previously announced by the company, according to an Investor Rights Agreement with the investors in the private placement, the company is required to file a resale registration statement to cover the shares underlying the notes and warrants sold by the company in the private placement. Such registration rights of investors are customary in similar private placement transactions, and the filing of the registration statement does not necessarily indicate whether any investor intends to convert the notes, exercise the warrants, or sell the common stock issuable upon such conversion or exercise.
